Digital Pathology Market - Global Forecast to 2029
商品番号 : SMB-13228
出版社 | MarketsandMarkets |
出版年月 | 2025年6月 |
ページ数 | 283 |
図表数 | 360 |
価格タイプ | シングルユーザライセンス |
価格 | USD 4,950 |
種別 | 英文調査報告書 |
本レポートは、製品、タイプ、用途、エンドユーザー、地域に基づいてデジタルパソロジー市場を分析しています。また、市場の成長に影響を与える要因(推進要因、機会、課題など)も分析しています。ステークホルダーにとっての市場機会と課題を評価し、市場リーダーの競争環境の詳細を提供します。さらに、ミクロ市場の成長傾向、見通し、そしてデジタルパソロジー市場全体への貢献についても調査しています。さらに、5つの主要地域における市場セグメントの収益予測も提供しています。
The market for digital pathology is segmented into three categories based on type: scanners, storage systems, and software. Given the significance of these devices in the digital pathology workflow, the scanners segment accounted for the largest share of the product category in 2024. Scanners are critical in enabling pathologists to view and analyze tissue samples on computer screens, as scanners convert physical glass slides to high-resolution digital images. The development of diagnostic remote access is paramount for improved accessibility and efficiency of pathology services by allowing pathologists to evaluate cases from any physical location, hence, the demand for scanners. The advancements in scanner technology, such as improved scanning rates and greater resolution imaging, have led to increased workflow, improved diagnostic accuracy, and value for investment for laboratories or medical facilities.
デジタルパソロジーの市場は、タイプに基づいてスキャナー、ストレージシステム、およびソフトウェアの3つのカテゴリに分類されます。デジタルパソロジーのワークフローにおけるこれらのデバイスの重要性を考えると、スキャナーセグメントは2024年に製品カテゴリで最大のシェアを占めました。スキャナーは、物理的なガラススライドを高解像度のデジタル画像に変換するため、病理学者がコンピューター画面で組織サンプルを表示および分析できるようにするために不可欠です。診断リモートアクセスの開発は、病理学者が物理的な場所から症例を評価できるようにすることで、病理学サービスのアクセス性と効率性を向上させるために最も重要であり、これがスキャナーの需要です。スキャン速度の向上や画像解像度の向上などのスキャナー技術の進歩は、ワークフローの増加、診断精度の向上、および研究室や医療施設の投資価値につながっています。

By type, the human pathology segment is expected to hold the largest share during the forecast period.
The human pathology segment is expected to occupy the largest share of the digital pathology market throughout the forecast period largely due to the rising global burden of complex and chronic diseases, including cancer, cardiovascular diseases, and infections, which demand timely and accurate diagnostic outcomes.
Digital pathology, examination, and diagnosis, typically performed under the eyepiece of a microscope, are advantageous in many aspects, such as producing high-resolution images, providing automated analytics, allowing for image storage, cloud storage, and telepathology slide-sharing services. Equally important is the unparalleled advantage of being able to provide remote consultation that may involve co-consultation and coordination at various sites and second opinions from specialists.
Furthermore, digital pathology is quickly being adopted and evolving to integrate the newest technologies such as artificial intelligence (AI), machine learning (ML), deep learning image recognition, which are all improving diagnostic accuracy, decreasing turnaround time, and even aiding in recognizing subtle histological patterns, which makes digital pathology a foundational element of practice in laboratories and hospitals around the world.
North America is expected to lead the global digital pathology market during the forecast period.
North America led the digital pathology market in 2024 due to a mature healthcare system and large financial investments toward developing healthcare technology. The regulatory environment in North America—especially in the US and Canada—supports a relatively faster review and approval process for emerging digital pathology technologies. This, combined with growing awareness among healthcare providers and rising demand for advanced diagnostic solutions, has driven strong adoption of digital pathology across the region.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
- By Designation: C-level (35%), Director-level (25%), and Others (40%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East & Africa (5%)
List of Companies Profiled in the Report
Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain)

Research Coverage
This report studies the digital pathology market based on product, type, application, end user, and region. The report also analyses factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total digital pathology market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers (Growing adoption of AI-enabled digital pathology, rising burden of cancer, diabetes, and chronic diseases, expansion of digital pathology in drug discovery and biomarker validation, Cancer screening programs in emerging markets), restraints (High initial capital costs, Data interoperability issues with existing lab systems, regulatory and reimbursement uncertainty), opportunities (Affordable scanner development for low-resource settings, growing preference for personalized medicine, government-backed digitization in emerging economies) challenges (Shortage of skilled pathologists and technicians, algorithm validation issues, data security and patient privacy concerns), are contributing the growth of the digital pathology market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market
- Market Development: Comprehensive information about lucrative markets and analysis of the authentication and brand protection market across varied regions
- Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the digital pathology market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology market
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED 30
1.3.3 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
1.5 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH APPROACH 32
2.1.1 SECONDARY DATA 32
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 34
2.1.2.1 Key data from primary sources 36
2.1.2.2 Key industry insights 36
2.2 RESEARCH METHODOLOGY DESIGN 37
2.3 MARKET SIZE ESTIMATION 38
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 43
2.5 RESEARCH ASSUMPTIONS 45
2.6 MARKET ASSUMPTIONS 45
2.6.1 OVERALL STUDY ASSUMPTIONS 45
2.7 RISK ASSESSMENT 46
2.8 RESEARCH LIMITATIONS 46
2.8.1 METHODOLOGY-RELATED LIMITATIONS 46
2.8.2 SCOPE-RELATED LIMITATIONS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 51
4.1 DIGITAL PATHOLOGY MARKET OVERVIEW 51
4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER AND COUNTRY (2024) 52
4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4.4 DIGITAL PATHOLOGY MARKET: REGIONAL MIX 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 55
5.2.1.1 AI-enabled digital pathology improving lab throughput 55
5.2.1.2 Rising burden of cancer, diabetes, and cardiovascular diseases 56
5.2.1.3 Expansion of digital pathology in drug discovery and biomarker validation 58
5.2.1.4 National cancer screening programs in emerging markets 58
5.2.2 RESTRAINTS 59
5.2.2.1 High initial capital cost of digital pathology systems 59
5.2.2.2 Data interoperability issues with existing lab systems 60
5.2.2.3 Regulatory and reimbursement uncertainty 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Affordable scanner development for low-resource settings 60
5.2.3.2 Personalized medicine driving precision diagnostics 61
5.2.3.3 Government-backed digitalization in emerging economies 62
5.2.4 CHALLENGES 62
5.2.4.1 Shortage of skilled pathologists and technicians 62
5.2.4.2 Algorithm validation and trust in AI-based diagnostics 62
5.2.4.3 Data security and privacy concerns 63
5.3 INDUSTRY TRENDS 63
5.3.1 AI-POWERED DIAGNOSTICS GO MAINSTREAM 63
5.3.2 CLOUD-BASED PLATFORMS AND REMOTE ACCESS BECOME CRITICAL ENABLERS 63
5.4 TECHNOLOGY ANALYSIS 64
5.4.1 CLOUD STORAGE & ARCHIVING 64
5.4.2 WHOLE SLIDE IMAGING (WSI) SCANNERS 64
5.4.3 IMAGE MANAGEMENT SYSTEMS 64
5.4.4 ADJACENT TECHNOLOGIES 64
5.4.4.1 Genomic sequencing 64
5.4.4.2 Artificial Intelligence and Machine Learning 65
5.4.5 COMPLEMENTARY TECHNOLOGIES 65
5.4.5.1 LIS & PACS 65
5.5 PRICING ANALYSIS 65
5.5.1 AVERAGE SELLING PRICE TREND, BY REGION 66
5.5.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 66
5.6 VALUE CHAIN ANALYSIS 66
5.7 ECOSYSTEM ANALYSIS 67
5.8 PORTER’S FIVE FORCES ANALYSIS 69
5.8.1 THREAT OF NEW ENTRANTS 70
5.8.2 THREAT OF SUBSTITUTES 70
5.8.3 BARGAINING POWER OF SUPPLIERS 70
5.8.4 BARGAINING POWER OF BUYERS 70
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.9 HS CODES 70
5.10 REGULATORY LANDSCAPE 71
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
5.10.2 REGULATORY ANALYSIS 72
5.10.2.1 North America 72
5.10.2.1.1 US 72
5.10.2.1.2 Canada 73
5.10.2.2 Europe 73
5.10.2.3 Asia Pacific 75
5.10.2.3.1 Japan 75
5.10.2.3.2 China 75
5.10.2.3.3 India 76
5.11 PATENT ANALYSIS 76
5.11.1 PATENT PUBLICATION TRENDS 76
5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS 77
5.11.3 MAJOR PATENTS 77
5.12 CASE STUDY ANALYSIS 79
5.13 KEY CONFERENCES & EVENTS, 2025–2026 80
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 81
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 81
5.14.2 BUYING CRITERIA 82
5.14.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 82
5.15 END-USER ANALYSIS 83
5.15.1 UNMET NEEDS 83
5.15.2 END-USER EXPECTATIONS 84
5.16 BUSINESS MODEL ANALYSIS 84
5.17 INVESTMENT & FUNDING SCENARIO 85
5.18 IMPACT OF AI ON DIGITAL PATHOLOGY MARKET 85
5.19 IMPACT OF US TARIFF ON DIGITAL PATHOLOGY MARKET 85
5.19.1 INTRODUCTION 85
5.19.2 KEY TARIFF RATES 86
5.20 PRICE IMPACT ANALYSIS 86
5.21 IMPACT ON COUNTRY/REGION 87
5.21.1 US 87
5.21.2 EUROPE 87
5.21.3 ASIA PACIFIC 87
5.21.4 IMPACT ON END-USE INDUSTRIES 87
6 DIGITAL PATHOLOGY MARKET, BY PRODUCT 88
6.1 INTRODUCTION 89
6.2 SCANNERS 89
6.2.1 BRIGHTFIELD SCANNERS 92
6.2.1.1 Cost-efficient features to boost demand 92
6.2.2 FLUORESCENCE SCANNERS 93
6.2.2.1 Ability to detect cellular structures and biomarkers to fuel uptake 93
6.2.3 OTHER SCANNERS 94
6.3 SOFTWARE 95
6.3.1 INTEGRATED SOFTWARE 97
6.3.1.1 Single & effective suite for multiple applications to propel market 97
6.3.2 STANDALONE SOFTWARE 98
6.3.2.1 Information management software 99
6.3.2.1.1 Management of image repositories to fuel uptake 99
6.3.2.2 Image analysis software 100
6.3.2.2.1 Ability to automate quantitative evaluation to support market growth 100
6.4 SOFTWARE, BY DEPLOYMENT MODEL 102
6.4.1 CLOUD-BASED MODEL 102
6.4.1.1 Facilitation of collaboration on a single platform to drive market 102
6.4.2 ON-PREMISE MODEL 104
6.4.2.1 High data security and integration with HCIT solutions to fuel uptake 104
6.4.3 HYBRID MODEL 105
6.4.3.1 Combined flexibility to support market growth 105
6.5 STORAGE SYSTEMS 106
6.5.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET 106
7 DIGITAL PATHOLOGY MARKET, BY TYPE 108
7.1 INTRODUCTION 109
7.2 HUMAN PATHOLOGY 109
7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET 109
7.3 VETERINARY PATHOLOGY 110
7.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH 110
8 DIGITAL PATHOLOGY MARKET, BY APPLICATION 112
8.1 INTRODUCTION 113
8.2 DRUG DISCOVERY 114
8.2.1 INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET 114
8.3 DISEASE DIAGNOSIS 115
8.3.1 INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND 115
8.4 TRAINING & EDUCATION 116
8.4.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH 116
9 DIGITAL PATHOLOGY MARKET, BY END USER 118
9.1 INTRODUCTION 119
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 119
9.2.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET 119
9.3 HOSPITALS & REFERENCE LABORATORIES 120
9.3.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND 120
9.4 ACADEMIC & RESEARCH INSTITUTES 122
9.4.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH 122
9.5 DIAGNOSTICS LABORATORIES 123
9.5.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH 123
9.6 VETERINARY LABORATORIES 124
9.6.1 TECHNOLOGICAL ADVANCEMENTS, PARTICULARLY IN WHOLE-SLIDE IMAGING SYSTEMS AND AI-POWERED IMAGE ANALYSIS SOFTWARE, SUPPORT MARKET GROWTH 124
10 DIGITAL PATHOLOGY MARKET, BY REGION 126
10.1 INTRODUCTION 127
10.2 NORTH AMERICA 127
10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 128
10.2.2 US 132
10.2.2.1 Favorable reimbursements for diagnostics to drive market 132
10.2.3 CANADA 135
10.2.3.1 Growing awareness on early cancer detection & diagnosis to drive market 135
10.3 EUROPE 139
10.3.1 EUROPE: MACROECONOMIC OUTLOOK 139
10.3.2 GERMANY 143
10.3.2.1 High healthcare expenditure and supportive research initiatives to drive market 143
10.3.3 UK 146
10.3.3.1 Government funding investments for pathology services to fuel market 146
10.3.4 SWEDEN 149
10.3.4.1 Increasing prevalence of chronic diseases to support market growth 149
10.3.5 FRANCE 152
10.3.5.1 Increasing government funding and favorable insurance system to drive adoption 152
10.3.6 SPAIN 154
10.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand 154
10.3.7 ITALY 156
10.3.7.1 Integration of AI & ML to support market growth 156
10.3.8 REST OF EUROPE 158
10.4 ASIA PACIFIC 160
10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 160
10.4.2 CHINA 166
10.4.2.1 Increasing establishment of hospitals and reference laboratories to drive market 166
10.4.3 JAPAN 168
10.4.3.1 Advanced healthcare infrastructure to support market growth 168
10.4.4 INDIA 171
10.4.4.1 Growth in pharmaceutical industry to propel market 171
10.4.5 REST OF ASIA PACIFIC 174
10.5 LATIN AMERICA 176
10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 176
10.5.2 BRAZIL 180
10.5.2.1 High adoption of POC testing to drive market 180
10.5.3 MEXICO 182
10.5.3.1 Growth in companion diagnostics to fuel uptake 182
10.5.4 REST OF LATIN AMERICA 184
10.6 MIDDLE EAST & AFRICA 186
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 186
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 187
10.6.3 GCC COUNTRIES 190
10.6.4 REST OF MIDDLE EAST & AFRICA 192
11 COMPETITIVE LANDSCAPE 195
11.1 OVERVIEW 195
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 195
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET 195
11.3 REVENUE ANALYSIS 197
11.4 MARKET SHARE ANALYSIS 197
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 200
11.5.1 STARS 200
11.5.2 EMERGING LEADERS 200
11.5.3 PERVASIVE PLAYERS 200
11.5.4 PARTICIPANTS 201
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 202
11.5.5.1 Company footprint 202
11.5.5.2 Product footprint 203
11.5.5.3 Application footprint 204
11.5.5.4 End-user footprint 205
11.5.5.5 Region footprint 206
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 207
11.6.1 PROGRESSIVE COMPANIES 207
11.6.2 RESPONSIVE COMPANIES 207
11.6.3 DYNAMIC COMPANIES 207
11.6.4 STARTING BLOCKS 207
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 209
11.7 COMPANY VALUATION AND FINANCIAL METRICS 211
11.8 BRAND/SOFTWARE COMPARATIVE ANALYSIS 212
11.9 COMPETITIVE SCENARIO 213
11.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 213
11.9.2 DEALS 214
11.9.3 OTHER DEVELOPMENTS 214
12 COMPANY PROFILES 215
12.1 KEY COMPANIES 215
12.1.1 DANAHER CORPORATION 215
12.1.1.1 Business overview 215
12.1.1.2 Products offered 216
12.1.1.3 Recent developments 217
12.1.1.3.1 Deals 217
12.1.1.4 MnM view 217
12.1.1.4.1 Key strengths 217
12.1.1.4.2 Strategic choices 217
12.1.1.4.3 Weaknesses and competitive threats 217
12.1.2 HOFFMANN-LA ROCHE LTD. 218
12.1.2.1 Business overview 218
12.1.2.2 Products offered 219
12.1.2.3 Recent developments 220
12.1.2.3.1 Product launches & approvals 220
12.1.2.3.2 Deals 220
12.1.2.4 MnM view 221
12.1.2.4.1 Key strengths 221
12.1.2.4.2 Strategic choices 221
12.1.2.4.3 Weaknesses and competitive threats 221
12.1.3 SECTRA AB 222
12.1.3.1 Business overview 222
12.1.3.2 Products offered 223
12.1.3.3 Recent developments 224
12.1.3.3.1 Deals 224
12.1.3.3.2 Other developments 226
12.1.3.4 MnM view 226
12.1.3.4.1 Key strengths 226
12.1.3.4.2 Strategic choices 226
12.1.3.4.3 Weaknesses and competitive threats 226
12.1.4 HAMAMATSU PHOTONICS K.K. 227
12.1.4.1 Business overview 227
12.1.4.2 Products offered 228
12.1.4.3 Recent developments 229
12.1.4.3.1 Product approvals 229
12.1.4.3.2 Deals 229
12.1.4.4 MnM view 230
12.1.4.4.1 Key strengths 230
12.1.4.4.2 Strategic choices 230
12.1.4.4.3 Weaknesses and competitive threats 230
12.1.5 KONINKLIJKE PHILIPS N.V. 231
12.1.5.1 Business overview 231
12.1.5.2 Products offered 232
12.1.5.3 Recent developments 233
12.1.5.3.1 Product launches & approvals 233
12.1.5.3.2 Deals 233
12.1.5.4 MnM view 234
12.1.5.4.1 Key strengths 234
12.1.5.4.2 Strategic choices 234
12.1.5.4.3 Weaknesses and competitive threats 234
12.1.6 AKOYA BIOSCIENCES, INC. 235
12.1.6.1 Business overview 235
12.1.6.2 Products offered 236
12.1.6.3 Recent developments 237
12.1.6.3.1 Product launches & approvals 237
12.1.7 FUJIFILM HOLDINGS CORPORATION 238
12.1.7.1 Business overview 238
12.1.7.2 Products offered 239
12.1.7.3 Recent developments 240
12.1.7.3.1 Deals 240
12.1.8 HOLOGIC, INC. 241
12.1.8.1 Business overview 241
12.1.8.2 Products offered 242
12.1.8.3 Recent developments 243
12.1.8.3.1 Product approvals 243
12.1.9 3DHISTECH LTD. 244
12.1.9.1 Business overview 244
12.1.9.2 Products offered 244
12.1.9.3 Recent developments 245
12.1.9.3.1 Product launches & enhancements 245
12.1.9.3.2 Other developments 246
12.1.10 APOLLO ENTERPRISE IMAGING CORP. 247
12.1.10.1 Business overview 247
12.1.10.2 Products offered 247
12.1.10.3 Recent developments 248
12.1.10.3.1 Product enhancements 248
12.1.10.3.2 Deals 248
12.1.11 XIFIN, INC. 249
12.1.11.1 Business overview 249
12.1.11.2 Products offered 249
12.1.11.3 Recent developments 249
12.1.11.3.1 Product launches 249
12.1.11.3.2 Deals 250
12.1.12 HURON DIGITAL PATHOLOGY 251
12.1.12.1 Business overview 251
12.1.12.2 Products offered 251
12.1.12.2.1 Deals 252
12.1.13 INDICA LABS 253
12.1.13.1 Business overview 253
12.1.13.2 Products offered 253
12.1.13.3 Recent developments 254
12.1.13.3.1 Product launches & approvals 254
12.1.13.3.2 Deals 254
12.1.14 OPTRASCAN, INC. 256
12.1.14.1 Business overview 256
12.1.14.2 Products offered 256
12.1.14.3 Recent developments 257
12.1.14.3.1 Product launches & approvals 257
12.1.14.3.2 Deals 257
12.1.15 GLENCOE SOFTWARE, INC. 258
12.1.15.1 Business overview 258
12.1.15.2 Products offered 258
12.1.15.3 Recent developments 259
12.1.15.3.1 Product enhancements 259
12.1.16 AIFORIA TECHNOLOGIES OY 260
12.1.16.1 Business overview 260
12.1.16.2 Products offered 260
12.1.16.3 Recent developments 261
12.1.16.3.1 Deals 261
12.1.17 PAIGE AI, INC. 262
12.1.17.1 Business overview 262
12.1.17.2 Products offered 262
12.1.17.3 Recent developments 263
12.1.17.3.1 Product launches & enhancements 263
12.1.17.3.2 Deals 263
12.1.18 PROSCIA, INC. 265
12.1.18.1 Business overview 265
12.1.18.2 Products offered 265
12.1.18.3 Recent developments 266
12.1.18.3.1 Product enhancements & approvals 266
12.1.18.3.2 Deals 266
12.2 OTHER PLAYERS 268
12.2.1 QUEST DIAGNOSTICS 268
12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD. 269
12.2.3 MIKROSCAN TECHNOLOGIES, INC. 270
12.2.4 MOTIC DIGITAL PATHOLOGY 271
12.2.5 KANTERON SYSTEMS 272
12.2.6 MORPHLE LABS INC. 272
12.2.7 EW HEALTHCARE PARTNERS 273
13 APPENDIX 274
13.1 DISCUSSION GUIDE 274
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 279
13.3 CUSTOMIZATION OPTIONS 281
13.4 RELATED REPORTS 281
13.5 AUTHOR DETAILS 282
LIST OF TABLES
TABLE 1 FACTOR ANALYSIS 41
TABLE 2 RISK ASSESSMENT ANALYSIS 46
TABLE 3 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 57
TABLE 4 AVERAGE SELLING PRICE TREND OF DIGITAL PATHOLOGY PRODUCTS, BY REGION 66
TABLE 5 AVERAGE SELLING PRICE OF DIGITAL PATHOLOGY PRODUCTS 66
TABLE 6 DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES 69
TABLE 7 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION 72
TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 72
TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 73
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES 74
TABLE 12 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 75
TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES 76
TABLE 14 LIST OF PATENTS/PATENT APPLICATIONS 78
TABLE 15 CASE STUDY 1: ASSESSING IMAGE QUALITY: A COMPARATIVE MULTI-ASSESSMENT EVALUATION OF APERIO GT 450 DX 79
TABLE 16 CASE STUDY 2: HOW TO PROMOTE PATHOLOGY WORKFLOW EFFICIENCY 79
TABLE 17 CASE STUDY 3: ARTIFICIAL INTELLIGENCE IN DIGITAL PATHOLOGY 80
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY PRODUCTS 81
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY, BY PRODUCT 81
TABLE 20 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS 82
TABLE 21 UNMET NEEDS IN DIGITAL PATHOLOGY MARKET 83
TABLE 22 END-USER EXPECTATIONS IN DIGITAL PATHOLOGY MARKET 84
TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES 86
TABLE 24 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 89
TABLE 25 SCANNING MAGNIFICATION AND APPLICATIONS 89
TABLE 26 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS 90
TABLE 27 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 91
TABLE 28 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY REGION,
2023–2030 (USD MILLION) 91
TABLE 29 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS 92
TABLE 30 BRIGHTFIELD SCANNERS MARKET, BY REGION, 2023–2030 (USD MILLION) 93
TABLE 31 FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS 93
TABLE 32 FLUORESCENCE SCANNERS MARKET, BY REGION, 2023–2030 (USD MILLION) 94
TABLE 33 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS 94
TABLE 34 OTHER SCANNERS MARKET, BY REGION, 2023–2030 (USD MILLION) 95
TABLE 35 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS 96
TABLE 36 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 96
TABLE 37 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY REGION,
2023–2030 (USD MILLION) 97
TABLE 38 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS 98
TABLE 39 INTEGRATED SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 98
TABLE 40 STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 99
TABLE 41 STANDALONE SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 99
TABLE 42 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS 100
TABLE 43 INFORMATION MANAGEMENT SOFTWARE MARKET, BY REGION,
2023–2030 (USD MILLION) 100
TABLE 44 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS 101
TABLE 45 IMAGE ANALYSIS SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 101
TABLE 46 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 102
TABLE 47 CLOUD-BASED SOFTWARE OFFERED BY KEY MARKET PLAYERS 103
TABLE 48 CLOUD-BASED MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 49 ON-PREMISE SOFTWARE OFFERED BY KEY MARKET PLAYERS 104
TABLE 50 ON-PREMISE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 51 HYBRID SOFTWARE OFFERED BY KEY MARKET PLAYERS 105
TABLE 52 HYBRID MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 53 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS 107
TABLE 54 DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY REGION,
2023–2030 (USD MILLION) 107
TABLE 55 DIGITAL PATHOLOGY MARKET, BY TYPE, 2023–2030 (USD MILLION) 109
TABLE 56 HUMAN DIGITAL PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 57 VETERINARY DIGITAL PATHOLOGY MARKET, BY REGION,
2023–2030 (USD MILLION) 111
TABLE 58 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 113
TABLE 59 SOFTWARE IMPACT ANALYSIS, BY APPLICATION 113
TABLE 60 DIGITAL PATHOLOGY APPLICATIONS IN DRUG DISCOVERY 114
TABLE 61 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 62 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY REGION,
2023–2030 (USD MILLION) 116
TABLE 63 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY REGION,
2023–2030 (USD MILLION) 117
TABLE 64 DIGITAL PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 119
TABLE 65 DIGITAL PATHOLOGY MARKET: SOFTWARE IMPACT ANALYSIS, BY END USER 119
TABLE 66 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 120
TABLE 67 DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS, BY HOSPITAL 121
TABLE 68 DIGITAL PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES,
BY REGION, 2023–2030 (USD MILLION) 122
TABLE 69 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2023–2030 (USD MILLION) 123
TABLE 70 DIGITAL PATHOLOGY MARKET FOR DIAGNOSTICS LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 71 DIGITAL PATHOLOGY MARKET FOR VETERINARY LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 125
TABLE 72 DIGITAL PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 73 NORTH AMERICA: MACROECONOMIC OUTLOOK, 2024 128
TABLE 74 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 129
TABLE 75 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 130
TABLE 76 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 130
TABLE 77 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 130
TABLE 78 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 131
TABLE 79 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 131
TABLE 80 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE,
2023–2030 (USD MILLION) 131
TABLE 81 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 132
TABLE 82 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 132
TABLE 83 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 133
TABLE 84 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 133
TABLE 85 US: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 134
TABLE 86 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 134
TABLE 87 US: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 134
TABLE 88 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 135
TABLE 89 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 136
TABLE 90 CANADA: FUNDING INITIATIVES FOR DIGITAL PATHOLOGY 136
TABLE 91 CANADA: KEY MACROINDICATORS 137
TABLE 92 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 137
TABLE 93 CANADA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 137
TABLE 94 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 138
TABLE 95 CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 138
TABLE 96 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 138
TABLE 97 EUROPE: MACROECONOMIC OUTLOOK 139
TABLE 98 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 99 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 140
TABLE 100 EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 140
TABLE 101 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 102 EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 103 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 141
TABLE 104 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 105 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 142
TABLE 106 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 142
TABLE 107 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 143
TABLE 108 GERMANY: KEY MACROINDICATORS 144
TABLE 109 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 144
TABLE 110 GERMANY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 144
TABLE 111 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 145
TABLE 112 GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 145
TABLE 113 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 145
TABLE 114 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 147
TABLE 115 UK: KEY MACROINDICATORS 147
TABLE 116 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 147
TABLE 117 UK: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 148
TABLE 118 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 148
TABLE 119 UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 148
TABLE 120 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 149
TABLE 121 SWEDEN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 150
TABLE 122 SWEDEN: KEY MACROINDICATORS 150
TABLE 123 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 150
TABLE 124 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 125 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 126 SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 151
TABLE 127 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 152
TABLE 128 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 152
TABLE 129 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 153
TABLE 130 FRANCE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 131 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 132 FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 133 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 154
TABLE 134 SPAIN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 155
TABLE 135 SPAIN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 155
TABLE 136 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 155
TABLE 137 SPAIN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 138 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 156
TABLE 139 ITALY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 157
TABLE 140 ITALY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 141 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 142 ITALY: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 143 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 158
TABLE 144 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 159
TABLE 145 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 159
TABLE 146 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 159
TABLE 147 REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 160
TABLE 148 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,
BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 160
TABLE 149 ASIA PACIFIC: MACROINDICATORS 161
TABLE 150 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 151 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 163
TABLE 152 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 163
TABLE 153 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 164
TABLE 154 ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 164
TABLE 155 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 164
TABLE 156 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2023–2030 (USD MILLION) 165
TABLE 157 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 165
TABLE 158 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 165
TABLE 159 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 166
TABLE 160 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 167
TABLE 161 CHINA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 167
TABLE 162 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 167
TABLE 163 CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 164 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 168
TABLE 165 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 169
TABLE 166 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 169
TABLE 167 JAPAN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 170
TABLE 168 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 170
TABLE 169 JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 170 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 171
TABLE 171 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 172
TABLE 172 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 172
TABLE 173 INDIA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 172
TABLE 174 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 173
TABLE 175 INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 173
TABLE 176 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 173
TABLE 177 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 174
TABLE 178 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 179 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 180 REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 175
TABLE 181 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,
BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 176
TABLE 182 LATIN AMERICA: MACROINDICATORS 176
TABLE 183 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 177
TABLE 184 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 177
TABLE 185 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 177
TABLE 186 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 178
TABLE 187 LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 178
TABLE 188 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 178
TABLE 189 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE,
2023–2030 (USD MILLION) 179
TABLE 190 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 179
TABLE 191 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 179
TABLE 192 BRAZIL: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 180
TABLE 193 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 180
TABLE 194 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 181
TABLE 195 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 181
TABLE 196 BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 197 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 182
TABLE 198 MEXICO: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 182
TABLE 199 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 183
TABLE 200 MEXICO: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 183
TABLE 201 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 183
TABLE 202 MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 203 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 184
TABLE 204 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 185
TABLE 205 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 206 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 207 REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 186
TABLE 208 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,
BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 186
TABLE 209 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 187
TABLE 210 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 187
TABLE 211 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 188
TABLE 212 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 213 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 214 MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE,
2023–2030 (USD MILLION) 189
TABLE 215 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,
BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 189
TABLE 216 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE,
2023–2030 (USD MILLION) 189
TABLE 217 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 190
TABLE 218 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 190
TABLE 219 GCC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 191
TABLE 220 GCC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE,
2023–2030 (USD MILLION) 191
TABLE 221 GCC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE,
2023–2030 (USD MILLION) 191
TABLE 222 GCC: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 223 GCC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 192
TABLE 224 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 193
TABLE 225 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 226 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 227 REST OF MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 228 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 194
TABLE 229 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 195
TABLE 230 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION 199
TABLE 231 DIGITAL PATHOLOGY MARKET: PRODUCT FOOTPRINT 203
TABLE 232 DIGITAL PATHOLOGY MARKET: APPLICATION FOOTPRINT 204
TABLE 233 DIGITAL PATHOLOGY MARKET: END-USER FOOTPRINT 205
TABLE 234 DIGITAL PATHOLOGY MARKET: REGION FOOTPRINT 206
TABLE 235 DIGITAL PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES 209
TABLE 236 DIGITAL PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 210
TABLE 237 DIGITAL PATHOLOGY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022–JUNE 2025 213
TABLE 238 DIGITAL PATHOLOGY MARKET: DEALS, JANUARY 2022–JUNE 2025 214
TABLE 239 DIGITAL PATHOLOGY MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–JUNE 2025 214
TABLE 240 DANAHER CORPORATION: COMPANY OVERVIEW 215
TABLE 241 DANAHER CORPORATION: PRODUCTS OFFERED 216
TABLE 242 DANAHER CORPORATION: DEALS, JANUARY 2022−JUNE 2025 217
TABLE 243 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 218
TABLE 244 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 219
TABLE 245 HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–JUNE 2025 220
TABLE 246 HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–JUNE 2025 220
TABLE 247 SECTRA AB: COMPANY OVERVIEW 222
TABLE 248 SECTRA AB: PRODUCTS OFFERED 223
TABLE 249 SECTRA AB: DEALS, JANUARY 2022–JUNE 2025 224
TABLE 250 SECTRA AB: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 226
TABLE 251 HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW 227
TABLE 252 HAMAMATSU PHOTONICS K.K.: PRODUCTS OFFERED 228
TABLE 253 HAMAMATSU PHOTONICS K.K.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025 229
TABLE 254 HAMAMATSU PHOTONICS K.K.: DEALS, JANUARY 2022–JUNE 2025 229
TABLE 255 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 231
TABLE 256 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 232
TABLE 257 KONINKLIJKE PHILIPS N.V: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 233
TABLE 258 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2022−JUNE 2025 233
TABLE 259 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW 235
TABLE 260 AKOYA BIOSCIENCES INC.: PRODUCTS OFFERED 236
TABLE 261 AKOYA BIOSCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–JUNE 2024 237
TABLE 262 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 238
TABLE 263 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED 239
TABLE 264 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JUNE 2025 240
TABLE 265 HOLOGIC, INC.: COMPANY OVERVIEW 241
TABLE 266 HOLOGIC, INC: PRODUCTS OFFERED 242
TABLE 267 HOLOGIC, INC: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 243
TABLE 268 3DHISTECH LTD.: COMPANY OVERVIEW 244
TABLE 269 3DHISTECH LTD.: PRODUCTS OFFERED 244
TABLE 270 3DHISTECH LTD.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–JUNE 2024 245
TABLE 271 3DHISTECH LTD.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2024 246
TABLE 272 APOLLO ENTERPRISE IMAGING CORP.: COMPANY OVERVIEW 247
TABLE 273 APOLLO ENTERPRISE IMAGING CORP.: PRODUCTS OFFERED 247
TABLE 274 APOLLO ENTERPRISE IMAGING CORP.: PRODUCT ENHANCEMENTS,
JANUARY 2022–JUNE 2025 248
TABLE 275 APOLLO ENTERPRISE IMAGING CORP.: DEALS, JANUARY 2022–JUNE 2025 248
TABLE 276 XIFIN, INC.: COMPANY OVERVIEW 249
TABLE 277 XIFIN, INC.: PRODUCTS OFFERED 249
TABLE 278 XIFIN, INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 249
TABLE 279 XIFIN, INC.: DEALS, JANUARY 2022–JUNE 2025 250
TABLE 280 HURON DIGITAL PATHOLOGY: COMPANY OVERVIEW 251
TABLE 281 HURON DIGITAL PATHOLOGY: PRODUCTS OFFERED 251
TABLE 282 HURON DIGITAL PATHOLOGY: DEALS, JANUARY 2022–JUNE 2025 252
TABLE 283 INDICA LABS: COMPANY OVERVIEW 253
TABLE 284 INDICA LABS: PRODUCTS OFFERED 253
TABLE 285 INDICA LABS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 254
TABLE 286 INDICA LABS: DEALS, JANUARY 2022–JUNE 2025 254
TABLE 287 OPTRASCAN, INC.: COMPANY OVERVIEW 256
TABLE 288 OPTRASCAN, INC.: PRODUCTS OFFERED 256
TABLE 289 OPTRASCAN, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–JUNE 2025 257
TABLE 290 OPTRASCAN, INC.: DEALS, JANUARY 2022–JUNE 2025 257
TABLE 291 GLENCOE SOFTWARE, INC.: COMPANY OVERVIEW 258
TABLE 292 GLENCOE SOFTWARE, INC.: PRODUCTS OFFERED 258
TABLE 293 GLENCOE SOFTWARE, INC.: PRODUCT ENHANCEMENTS,
JANUARY 2022–JUNE 2025 259
TABLE 294 AIFORIA TECHNOLOGIES OY: COMPANY OVERVIEW 260
TABLE 295 AIFORIA TECHNOLOGIES OY: PRODUCTS OFFERED 260
TABLE 296 PAIGE AI, INC.: COMPANY OVERVIEW 262
TABLE 297 PAIGE AI, INC.: PRODUCTS OFFERED 262
TABLE 298 PAIGE AI, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022–JUNE 2025 263
TABLE 299 PAIGE AI, INC.: DEALS, JANUARY 2022–JUNE 2025 263
TABLE 300 PROSCIA, INC.: COMPANY OVERVIEW 265
TABLE 301 PROSCIA, INC.: PRODUCTS OFFERED 265
TABLE 302 PROSCIA, INC.: PRODUCT ENHANCEMENTS & APPROVALS,
JANUARY 2022–JUNE 2025 266
TABLE 303 PROSCIA, INC.: DEALS, JANUARY 2022–JUNE 2025 266
TABLE 304 QUEST DIAGNOSTICS: COMPANY OVERVIEW 268
TABLE 305 KONFOONG BIOTECH INTERNATIONAL CO., LTD.: COMPANY OVERVIEW 269
TABLE 306 MIKROSCAN TECHNOLOGIES, INC.: COMPANY OVERVIEW 270
TABLE 307 MOTIC DIGITAL PATHOLOGY: COMPANY OVERVIEW 271
TABLE 308 KANTERON SYSTEMS: COMPANY OVERVIEW 272
TABLE 309 MORPHLE LABS INC.: COMPANY OVERVIEW 272
TABLE 310 EW HEALTHCARE PARTNERS: COMPANY OVERVIEW 273
LIST OF FIGURES
FIGURE 1 DIGITAL PATHOLOGY MARKET 29
FIGURE 2 RESEARCH DESIGN 32
FIGURE 3 PRIMARY SOURCES 35
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE,
DESIGNATION, AND REGION 36
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 37
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 38
FIGURE 7 DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS OF DANAHER CORPORATION 39
FIGURE 8 BOTTOM-UP APPROACH 40
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DIGITAL PATHOLOGY MARKET (2025–2030) 42
FIGURE 11 DATA TRIANGULATION METHODOLOGY 44
FIGURE 12 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 47
FIGURE 13 DIGITAL PATHOLOGY MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 48
FIGURE 14 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 48
FIGURE 15 DIGITAL PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 49
FIGURE 16 GEOGRAPHIC SNAPSHOT OF DIGITAL PATHOLOGY MARKET 50
FIGURE 17 RISING INCIDENCE OF CANCER AND GROWING ADOPTION OF PATHOLOGY SOLUTIONS FOR ENHANCED LAB EFFICIENCY TO DRIVE MARKET 51
FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 52
FIGURE 19 UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 53
FIGURE 20 ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 54
FIGURE 21 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
FIGURE 22 GLOBAL CANCER INCIDENCE, 2008−2030 57
FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015−2022 61
FIGURE 24 DIGITAL PATHOLOGY MARKET: VALUE CHAIN ANALYSIS 67
FIGURE 25 DIGITAL PATHOLOGY MARKET: ECOSYSTEM ANALYSIS 68
FIGURE 26 DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 69
FIGURE 27 EUROPE: IVDR TIMELINE 74
FIGURE 28 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR
DIGITAL PATHOLOGY PATENTS, 2014–2025 77
FIGURE 29 MAJOR PATENTS FOR DIGITAL PATHOLOGY (2015–2025) 77
FIGURE 30 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS 82
FIGURE 31 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 83
FIGURE 32 RECENT FUNDING OF PLAYERS IN DIGITAL PATHOLOGY MARKET 85
FIGURE 33 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT 129
FIGURE 34 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET SNAPSHOT 162
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET 197
FIGURE 36 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS 198
FIGURE 37 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 201
FIGURE 38 DIGITAL PATHOLOGY MARKET: COMPANY FOOTPRINT 202
FIGURE 39 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2024 208
FIGURE 40 EV/EBITDA OF KEY VENDORS 211
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF DIGITAL PATHOLOGY VENDORS 211
FIGURE 42 DIGITAL PATHOLOGY MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS 212
FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 216
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 219
FIGURE 45 SECTRA AB: COMPANY SNAPSHOT (2024) 223
FIGURE 46 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2024) 228
FIGURE 47 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024) 232
FIGURE 48 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024) 236
FIGURE 49 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 239
FIGURE 50 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 242
MarketsandMarkets(マーケッツアンドマーケッツ)は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間~12時間以内(営業日基準)にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
シングルユーザ | コーポレート |
USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨(定価)を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料(ハンドリングチャージ)無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内(関連会社除く)5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100%持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内(営業日基準)
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 水性バリアコーティング市場 – 2030年までの世界予測 2025-07-03
- 工作機械市場 – 2032年までの世界予測 2025-07-03
- 軟組織修復市場 – 2030年までの世界予測 2025-07-02
- エポキシ樹脂市場 – 2030年までの世界予測 2025-07-02
- スマートガスメーター市場 – 2030年までの世界予測 2025-07-02